DAX ®13.054,80-0,65%TecDAX ®3.037,12-0,16%Dow Jones27.677,79+0,10%NASDAQ 1008.308,40+0,14%

DGAP-Adhoc: QIAGEN N.V.: QIAGEN receives several conditional, non-binding indications of interest, and decides to enter into discussions to explore potential strategic alterna-tives

| Quelle: Dow Jones Newsw... | Lesedauer etwa 5 min. | Text vorlesen Stop Pause Fortsetzen

DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Offer/Takeover
QIAGEN N.V.: QIAGEN receives several conditional, non-binding indications of
interest, and decides to enter into discussions to explore potential
strategic alterna-tives

15-Nov-2019 / 21:20 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

*Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation*

*QIAGEN receives several conditional, non-binding indications of interest,
and decides to enter into discussions to explore potential strategic

*Venlo, The Netherlands, November 15, 2019 -* QIAGEN N.V. (NYSE: QGEN;
Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces it has
begun a review of potential strategic alternatives after receiving several
conditional, non-binding indications of interest for the acquisition of all
issued and outstanding shares of the Company.

The Supervisory Board and the Management Board of QIAGEN, in accordance with
their fiduciary duties and as part of the review of potential strategic
alternatives, are starting discussions with interested parties. These
discussions aim to explore potential strategic alternatives that could
provide greater value creation opportunities than the already strong
stand-alone growth prospects for the Company, taking into consideration the
interests of QIAGEN's stakeholders including its shareholders.

There is no guarantee or certainty that these discussions will lead to a
recommended firm offer to all shareholders of the Company.

Further announcements will be made if and when required.

Certain statements contained in this press release may be considered
forward-looking statements within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended. Such statements include statements with
respect to the Company's strategic plans and exploration of strategic
alternatives. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,'
'believes,' 'seeks,' 'estimates,' and similar expressions are intended to
identify forward-looking statements. All statements contained in this
announcement that do not relate to matters of historical fact should be
considered forward-looking statements, including with respect to the status
of any discussions with potential counterparties, the possibility of
completing a transaction, and any outcome of a strategic alternative
evaluation process. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements to be
materially different from our expectations expressed or implied by the
forward-looking statements, including, but not limited to, the general
uncertainty around future plans for the Company. Additionally, the Company's
exploration of strategic alternatives represents a potential material change
in business strategy, which the Company may not be able to execute
effectively, on any specific timeline, or at all, and its failure to do so
may impact the price and volatility of the Company's publicly traded shares.
These risks and uncertainties could cause actual results to differ
materially from those indicated by the forward-looking statements made in
this announcement. Such forward-looking statements also are subject to risks
and uncertainties related to the Company's business, including but not
limited to, risks associated with management of growth and international
operations (including the effects of currency fluctuations, regulatory
processes and dependence on logistics); variability of operating results and
allocations between customer classes; the commercial development of markets
for our products to customers in academia, pharma, applied testing and
molecular diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and timing of
customers' funding, budgets and other factors); our ability to obtain
regulatory approval of our products; difficulties in successfully adapting
QIAGEN's products to integrated solutions and producing such products; the
ability of QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market acceptance of
QIAGEN's new products and the integration of acquired technologies and
businesses; and the other factors discussed under the heading "Risk Factors"
contained in Item 3 of our most recent Annual Report on Form 20-F. For
further information, please refer to the discussions in reports that QIAGEN
has filed with, or furnished to, the U.S. Securities and Exchange Commission
(SEC). Any such forward-looking statements represent management's estimates
as of the date of this announcement. While we may elect to update such
forward-looking statements at some point in the future, we disclaim any
obligation to do so, even if subsequent events cause our views to change,
except as required by law or by any appropriate regulatory authority. These
forward-looking statements should not be relied upon as representing our
views as of any date subsequent to the date of this announcement.


*Hulsterweg 82*

*5912 PL Venlo*

*The Netherlands*

*ISIN: NL0012169213*

Frankfurt Stock Exchange, regulated market (Prime Standard)


John Gilardi
Vice President, Head of Corporate Communications and Investor Relations
+49 2103 29 11711 and +1 240 686 2222

15-Nov-2019 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Phone: +31 7735566 - 00
Fax: +31 77 35566-58
E-mail: qiagen@qiagen.com
Internet: www.qiagen.com
ISIN: NL0012169213
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard);
Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE,
EQS News ID: 914719

End of Announcement DGAP News Service

914719 15-Nov-2019 CET/CEST

(END) Dow Jones Newswires

November 15, 2019 15:21 ET ( 20:21 GMT)

Das könnte Sie auch interessieren



Aktuelle Videos

zur Mediathek

Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Was wünschen Sie sich von der Großen Koalition?
Jetzt abstimmen!
Alle Umfragen ansehen